Staffordshire University

About: Staffordshire University is a education organization based out in Stoke-on-Trent, United Kingdom. It is known for research contribution in the topics: Population & Mental health. The organization has 2046 authors who have published 4490 publications receiving 102847 citations. The organization is also known as: North Staffordshire Polytechnic.

Body Image: Understanding Body Dissatisfaction in Men, Women and Children

Abstract: Sarah Grogan provides a comprehensive overview of the subject of body image, pulling together diverse research from the fields of psychology, sociology, media, and gender studies in men, women, and children. This second edition has been thoroughly revised and updated to reflect the significant increase in research on body image since the first edition was published, including new empirical data collected specifically for this text. In addition to examining evidence for sociocultural influences on body image, the book also reviews recent literature and includes new findings on body modification practices (cosmetic surgery, piercing, tattooing, and bodybuilding). It takes a critical look at interventions designed to promote positive body image and also attempts to link body image to physical health, looking in particular at motivations for potentially health-damaging practices such as anabolic steroid use and cosmetic surgery. The only text to date that examines the issue of body image, focusing on men and children as well as women, Body Image will be invaluable to students and researchers in the area as well as those with an interest in how to promote positive body image.

Performing tourism, staging tourism (Re)producing tourist space and practice

Abstract: This article explores the metaphor of performance to investigate how tourism can be conceived as a set of activities, imbricated with the everyday, whereby conventions are reinforced and broken. By looking at the contexts in which tourism is regulated, directed and choreographed or, alternatively, is a realm of improvisation and contestation, I will consider the constraints and opportunities which shape the ways in which tourist space (here considered as ‘stages’) and performance are reproduced, challenged, transformed and bypassed. A range of examples will be used to exemplify the ways in which tourism is staged and performed. I will also focus on how the global proliferation of tourist practices and attractions acts to theme tourist space in highly commodified ways and simultaneously decentre normative modes of performing tourism.

Phase III Randomized Comparison of Gemcitabine Versus Gemcitabine Plus Capecitabine in Patients With Advanced Pancreatic Cancer

Abstract: Purpose Both gemcitabine (GEM) and fluoropyrimidines are valuable treatment for advanced pancreatic cancer. This open-label study was designed to compare the overall survival (OS) of patients randomly assigned to GEM alone or GEM plus capecitabine (GEM-CAP). Patients and Methods Patients with previously untreated histologically or cytologically proven locally advanced or metastatic carcinoma of the pancreas with a performance status ≤ 2 were recruited. Patients were randomly assigned to GEM or GEM-CAP. The primary outcome measure was survival. Meta-analysis of published studies was also conducted. Results Between May 2002 and January 2005, 533 patients were randomly assigned to GEM (n = 266) and GEM-CAP (n = 267) arms. GEM-CAP significantly improved objective response rate (19.1% v 12.4%; P = .034) and progression-free survival (hazard ratio [HR], 0.78; 95% CI, 0.66 to 0.93; P = .004) and was associated with a trend toward improved OS (HR, 0.86; 95% CI, 0.72 to 1.02; P = .08) compared with GEM alone. This trend for OS benefit for GEM-CAP was consistent across different prognostic subgroups according to baseline stratification factors (stage and performance status) and remained after adjusting for these stratification factors (P = .077). Moreover, the meta-analysis of two additional studies involving 935 patients showed a significant survival benefit in favor of GEM-CAP (HR, 0.86; 95% CI, 0.75 to 0.98; P = .02) with no intertrial heterogeneity. Conclusion On the basis of our trial and the meta-analysis, GEM-CAP should be considered as one of the standard first-line options in locally advanced and metastatic pancreatic cancer.